HLK Pharmacin

HLK Pharmacin is committed to improving patient outcomes through the development of best-in-class therapeutics.

Number of Funding Rounds

Total Funding Amount

1

—

HLK Pharmacin has raised a total of — in funding over 2 rounds. Their latest funding was raised on Aug 31, 2021 from a Series B round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Aug 31, 2021	Series B	—	2	—	—	Detail

Number of Lead Investors

Number of Investors

—

2

HLK Pharmacin is funded by 2 investors. Qingdao Medicine and DaYou Capital are the most recent investors.

Investor Name	Lead Investor	Funding Round
Qingdao Medicine	—	Series B
DaYou Capital	—	Series B